ACE-031
Original price was: $115.00.$56.00Current price is: $56.00.
Description:
ACE-031 is a synthetic polypeptide designed as a soluble form of the activin receptor type IIB (ActRIIB) extracellular domain. Produced through controlled peptide synthesis, it functions as a decoy receptor that binds and neutralizes myostatin and other TGF-β superfamily ligands that negatively regulate muscle growth.
Product Usage: For Research Use Only – Not for Human or Veterinary Use
This product is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA. Not intended for human or veterinary use, medical treatment, or diagnostic applications. The purchaser assumes all responsibility for compliance with applicable regulations.
Research Applications:
ACE-031 is utilized in controlled laboratory research settings for applications such as:
- Investigation of myostatin/ActRIIB signaling pathways and their role in muscle growth regulation
- Examination of skeletal muscle hypertrophy, fiber cross-sectional area, and lean mass increases in cell and animal models
- Evaluation of muscle regeneration and repair mechanisms in models of muscle wasting or dystrophy
- Characterization of metabolic effects, including impacts on fat mass, bone density, and overall body composition
Storage and Handling:
- Store lyophilized powder at -20°C.
- Once reconstituted, store at 2-8°C and use promptly.
- Use aseptic techniques during handling to maintain sterility and quality.
Product Specifications:
Purity: ≥99% (HPLC Certified)
Appearance: Lyophilized White Powder
Solubility: Soluble In Suitable Laboratory Agents
Compliance Notice:
ACE-031 is FOR RESEARCH USE ONLY. They are not intended for human or veterinary use. This product has not been evaluated by the FDA. Misuse of this product is strictly prohibited and may violate federal, state, or local laws. By purchasing this product, the buyer represents and warrants that it will be used only for in vitro research purposes.
| Size |
10mg*10vials |
|---|
Reviews
There are no reviews yet.